Biotinylated Human EGFRvIII Protein, His,Avitag™ (MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
EGR-H82E0-25ug
$380.00
EGR-H82E0-200ug
$1645.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    EGFRvIII

  • Source

    Biotinylated Human EGFRvIII, His,Avitag (EGR-H82E0) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).

    Predicted N-terminus: Leu 25

    Request for sequence
  • Molecular Characterization

    EGFRvIII Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 42.2 kDa. The protein migrates as 60-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    EGFRvIII SDS-PAGE

    Biotinylated Human EGFRvIII, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    EGFRvIII SEC-MALS

    The purity of Biotinylated Human EGFRvIII, His,Avitag (Cat. No. EGR-H82E0) is more than 95% and the molecular weight of this protein is around 60-70 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     EGFRvIII ELISA

    Immobilized Biotinylated Human EGFRvIII, His,Avitag (Cat. No. EGR-H82E0) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-EGFRvIII Antibody, Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  •  EGFRvIII ELISA

    Immobilized CetuxiMab at 1 μg/mL (100 μL/well) can bind Biotinylated Human EGFRvIII, His,Avitag (Cat. No. EGR-H82E0) with a linear range of 0.2-2 ng/mL (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Epidermal growth factor receptor variant III

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    14 詳細

  • 最新の開発ステージ:

    Phase 2 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8